Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. - Wikidata - wikimedia - TriplyDB

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.

http://www.wikidata.org/entity/Q34743817

about

EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment Treatment of primary Sjögren syndrome.Characterization and risk estimate of cancer in patients with primary Sjögren syndrome Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.The Diagnosis and Treatment of Sjögren's Syndrome.Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.Association of serum TNF-α, IL-8 and free light chain with HLA-DR B alleles expression in pulmonary and extra-pulmonary sarcoidosis Distribution of Peripheral Lymphocyte Populations in Primary Sjögren's Syndrome Patients.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome.Acupuncture for Primary Sjögren Syndrome (pSS) on symptomatic improvements: study protocol for a randomized controlled trial.Whole exome sequencing of a consanguineous family identifies the possible modifying effect of a globally rare AK5 allelic variant in celiac disease development among Saudi patients Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome Long non-coding RNA expression profile in minor salivary gland of primary Sjögren's syndrome.Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.Predicting progression to lymphoma in Sjögren's syndrome patients.B-cell hyperactivity in primary Sjögren's syndrome.Classification criteria and treatment modalities in primary Sjögren's syndrome.Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management.Renal involvement in primary Sjögren syndrome.Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.Updates on Sjögren's syndrome: from proteomics to protein biomarkers.Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation.Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome.B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome.Diagnostic accuracy of salivary and serum-free light chain assays in primary Sjögren's syndrome: a pilot study.Sjögren syndrome

P2860

Q26778262-AEF1CF06-ABF2-45F0-9524-A4075E46F275 Q30234992-69D358EC-66E3-49D5-88BC-9237C29983D4 Q30249011-EB08F62A-3756-4F3F-AE40-37E537B113D0 Q33568158-EC156EBE-BC2F-4DB9-A54D-B02F25C6765B Q33667694-2C6FD00A-675C-4165-8AD5-0925F084D95A Q33799767-9EF5CE3C-3764-4E42-9AC9-7BCDB56DACA2 Q33800932-8B5B2F53-8077-4F4C-9484-ABBC7751096D Q33831656-02ECF321-8496-47C6-8720-CC834296394A Q35130185-ABB5FC3A-D75E-4655-86B3-705662F5AEFA Q35372594-CB9C0697-0231-40E2-9C67-FB55A48E0B65 Q35673732-97D9AE03-5329-44BC-8E05-4AC6EAF915A8 Q35774612-308F6417-78B8-404B-8C67-B7CDA70B27E7 Q36027561-8953D4DA-881C-4269-87C1-D97F9FE3D801 Q36183852-18F01251-4A25-4F97-B420-C294A121A9FB Q36219673-3FC9779F-C347-4EA6-B45B-26BE4FE7F98E Q36254489-D4B8A8D6-6937-47F1-B9BD-4BCF7E6A3AB5 Q36372139-203A9178-8FF3-4618-936B-5453872367FA Q36903959-17ADBA68-55D9-4C9C-9FF0-FFF9CC713286 Q36907367-7974652F-F8DF-494A-B471-8B27C748BAD0 Q37542648-FEAA8FB1-9051-4891-9A7D-81EF6FE1E4E1 Q38180823-E684B1B5-B575-4547-AAD7-3FA2B42E87B5 Q38190590-D208CFC0-8E90-478C-99FE-13C08AB21B5A Q38197287-595FBAB4-E7C5-4056-BF99-E50BE4F40239 Q38260354-502859D4-8637-4DF9-A02F-CAB940CB3104 Q38633492-E46A7C46-09FF-40F0-9725-6F49E0158B35 Q38905170-0233A5C3-99FC-4812-91DF-C5B02456EAFB Q39081726-2DD5B660-D5BC-44EB-884D-F82353ABD921 Q39292745-15AB7377-32F5-4666-B81D-08BC432BEFC8 Q39322769-91F306CE-D4F6-47B1-8DDF-E8E8C4878CC1 Q39791068-290AEE24-8D1C-45CC-9057-B1662907DBB3 Q40550187-C06E5E85-1809-4FE3-94AA-51CD8F27AD71 Q41652024-C9CCC752-66E6-4E09-AAE4-2909D73E8AAA Q46223982-A8809190-1BCE-43E8-A399-68472B44A815 Q52334544-373305DE-04E9-4A69-A3F6-FDEF20F89D76 Q53602479-57C503D9-5F7B-472E-B3C9-4F50EC9CAF95 Q55970262-A43180DC-83E5-4447-9DCA-27CB976F3CCB

P2860

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.

http://www.wikidata.org/entity/Q34743817

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@ast

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@en

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@nl

type

label

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@ast

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@en

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@nl

prefLabel

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@ast

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@en

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@nl

P1433

Q34743817-768C7255-4723-4359-807D-21A943247918

P1476

Q34743817-A35975C3-2CAD-4131-B648-B522C0E65803

P2093

Q34743817-10B3A49C-EE64-4A4F-964E-73BE189DB197

Q34743817-248A169A-8200-4E58-87A6-1EFA275660E4

Q34743817-27FA5AA2-3D5C-4C9E-8579-0FC488F8BAC3

Q34743817-29668F95-C4ED-4202-8E6F-45C6853F4586

Q34743817-3BCC7598-3FE0-48D3-AC45-DD1EBCCCA4D2

Q34743817-3CF3DEBC-4326-4914-B10F-082AA0A2E3D9

Q34743817-3E95DDCA-140E-4C8B-AE93-25399EE8C541

Q34743817-4D19F21C-85B4-4C34-8E8F-36165FB3D58F

Q34743817-561E35D1-3D19-493A-BE93-4B2A00F038D6

Q34743817-5A4D5DC2-058C-4495-84FB-D453B4044B01

P2860

Q34743817-06B55E1A-86EA-45A9-A57D-51D5FDABD310

Q34743817-08C362D9-1E55-4E8D-9A29-0C90F8558F28

Q34743817-0FFE93B1-DF70-45B9-B057-8A6580EDFD71

Q34743817-12E0ADA2-FE55-4412-82DC-6BD6369EB713

Q34743817-2DC1AAEE-DA04-4A10-BF72-93320E3AEC86

Q34743817-35D54BA3-C9FA-4EDA-B9C1-38510B5A656F

Q34743817-36E787D8-D77E-4C69-A1F9-B68F048A418A

Q34743817-3BA6E15C-7E27-403B-9A60-6E659C80E52A

Q34743817-46AE7BBE-2BEE-4069-81DE-378AE1820A55

Q34743817-47193432-6D0E-4B5D-BBA5-5E1ED42DEDAD

P304

Q34743817-9D82E5EC-E83D-4AC8-ABBF-25C8ABCCD20C

P31

Q34743817-598E6C2E-3DE1-47C3-863B-5152D2E0D96B

P356

Q34743817-8C7FB8C7-EA29-4E78-B50A-DA54A6769D57

P407

Q34743817-098A3B2C-39F3-4E7A-9F67-2BE28FD0AC35

P433

Q34743817-7006AD22-CACE-47ED-938F-979C5847550B

P478

Q34743817-01C703B9-8B15-47D2-8453-75B3C4ECFB54

P50

Q34743817-0544571C-F26A-4886-B35C-AFBA45F232E8

Q34743817-2452B93E-D038-49EE-90B5-F29743E24AC0

Q34743817-26BA8479-7F90-403E-9785-247F10DA33DE

Q34743817-2F622E6C-035D-42A5-AA23-0B2874D57FEF

Q34743817-7CBC9355-A0F4-492F-83FF-9604CEC18D24

Q34743817-9C42C3F1-0F0B-4ADC-9FE0-4266A724F99D

Q34743817-A844CC51-D12A-472D-AD70-975A4FA937A7

Q34743817-CF8BF370-1D15-427E-9EB1-A50105579484

Q34743817-EB318F41-D556-4046-B8F3-94440B741176

Q34743817-F272900C-5730-411A-9DFD-27F186011614

P577

Q34743817-C77C1E06-64B0-43BB-AAA6-F699597DFDCD

P5875

Q34743817-6CEEDF4F-72A3-4CCB-A064-ECA2584B2CBF

P698

Q34743817-B476BF59-D17D-4CBB-9387-534D85F6AECE

P932

Q34743817-0E3E61D0-10F4-4E1C-9467-EDBC9B5582C4

P356

JOURNAL.PONE.0059868

P1433

P1476

Serum levels of beta2-microglo ...... the prospective ASSESS cohort.

@en

P2093

Aleth Perdriger

http://www.w3.org/2001/XMLSchema#string

Anne-Laure Fauchais

http://www.w3.org/2001/XMLSchema#string

Claire Larroche

http://www.w3.org/2001/XMLSchema#string

Corinne Miceli-Richard

http://www.w3.org/2001/XMLSchema#string

Damien Sene

http://www.w3.org/2001/XMLSchema#string

Gaétane Nocturne

http://www.w3.org/2001/XMLSchema#string

Jacques Morel

http://www.w3.org/2001/XMLSchema#string

Jean Sibilia

http://www.w3.org/2001/XMLSchema#string

Jean-Jacques Dubost

http://www.w3.org/2001/XMLSchema#string

Joelle Benessiano

http://www.w3.org/2001/XMLSchema#string

P2860

Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force

In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response.

High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome

Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.

Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors

Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.

Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

P304

e59868

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0059868

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Ravaud

Philippe Dieudé

Xavier Puéchal

Valérie Devauchelle-Pensec

Jacques-Eric Gottenberg

Raphaèle Seror

Corinne Miceli-Richard

P577

2013-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236959466

http://www.w3.org/2001/XMLSchema#string

P698

23717383

http://www.w3.org/2001/XMLSchema#string

P932

3663789

http://www.w3.org/2001/XMLSchema#string